IT   EN

Ultimi tweet

Moderate to severe plaque psoriasis, New long-term complete skin clearance data for bimekizumab (Bimzelx®)

UCB, a global biopharmaceutical company, today announced that it is presenting 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, Massachusetts, U.S., on March 25-29, including a late breaking oral platform presentation and 10 posters.

The platform presentation details new analysis of pooled data from five bimekizumab Phase 3/3b clinical trials, which showed that over 80 percent of patients who achieved complete skin clearance (PASI100) at week 16 and entered the open-label extension (OLE) studies maintained this response through two years follow up, and no new safety signals were identified.1

Among the poster presentations, new data from the OLE period of the Phase 3b BE RADIANT study showed that clinical responses (PASI100 and absolute PASI, PASI ≤2) achieved at week 48 were maintained through week 96 with continuous treatment with bimekizumab and improved for patients who switched from secukinumab to bimekizumab on entry to the OLE.2,3  Patients who were PASI90 non-responders with secukinumab at week 48 achieved improved clinical responses (PASI90 and PASI100) after switching to bimekizumab in the OLE.3 Among patients who were PASI90 responders with secukinumab at week 48, PASI90 response was maintained and PASI100 response increased following switch to bimekizumab in the OLE.3

In the European Union and Great Britain, bimekizumab is the first selective IL-17A and IL-17F inhibitor to be approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.4,5 Bimekizumab is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults. 

“Long term complete skin clearance is an important goal for people with psoriasis, and the new 96-week data from the open-label extension period of the BE RADIANT study offer fresh insights on the sustained response and clinical potential of bimekizumab in moderate to severe plaque psoriasis,” said Bruce Strober, M.D., Ph.D., Clinical Professor, Department of Dermatology, Yale University School of Medicine, New Haven, CT, U.S., and Central Connecticut Dermatology Research, Cromwell, CT, U.S. “In addition, the improved clinical responses seen in patients who switched to bimekizumab after 48 weeks of treatment with secukinumab offer further new insights that should help to inform future clinical practice.” 

Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB, said: “We are pleased to share our latest long-term data on bimekizumab with the dermatology community at the 2022 AAD Annual Meeting. The wealth of new data, insights and progress being presented underlines our commitment to advances in psoriasis care for people living with this challenging, life-long condition.” 

Phase 3/3b studies: two-year pooled data for bimekizumab in patients with moderate to severe plaque psoriasis1¥

Data were pooled from the BE VIVID, BE READY, and BE SURE Phase 3 trials, the Phase 3b BE RADIANT trial and OLE (48 weeks), and the first year of the BE BRIGHT OLE study. Analysis evaluated PASI100 maintenance through two years (OLE 48 weeks) among PASI100 week 16 responders who entered the respective OLE studies and received continuous bimekizumab maintenance dosing from week 16 (320 mg every four weeks [Q4W/Q4W/Q4W] or Q4W/Q8W/Q8W*). At week 16, 62.4 percent of bimekizumab-treated patients (n=850) achieved PASI100. Of those who entered the OLEs, 85.1 percent (Q4W/Q4W/Q4W; n=316) and 83.8 percent (Q4W/Q8W/Q8W*; n=267) maintained PASI100 at year two (OLE week 48). The exposure-adjusted incidence rates (EAIRs) of overall and serious treatment emergent adverse events (TEAEs) were 192.7 and 5.9. The most common TEAEs were nasopharyngitis (EAIR of 18.4), oral candidiasis (13.0) and upper respiratory tract infections (7.8). Almost all cases of oral candidiasis (98.1 percent) were mild or moderate.

BE RADIANT open-label extension study in patients with moderate to severe plaque psoriasis: efficacy and safety data through 96 weeks2                                                

Complete skin clearance (PASI100) levels observed with bimekizumab in the BE RADIANT study were maintained in the OLE through week 96 (74.8 percent and 70.6 percent at weeks 48 and 96, respectively) and improved for patients who switched from secukinumab to bimekizumab on entry to the OLE period (52.8 percent and 76.1 percent at weeks 48 and 96, respectively). The absolute PASI response (PASI≤2) was also maintained through week 96 (94.3 percent and 93.4 percent at weeks 48 and 96, respectively) and improved for patients who switched from secukinumab to bimekizumab on entry to the OLE period (83.9 percent and 94.6 percent at weeks 48 and 96, respectively). During the OLE, the most common adverse events with bimekizumab were nasopharyngitis (11.8/100 patient-years), oral candidiasis (7.8/100 patient-years), and urinary tract infection (4.5/100 patient-years). Adverse events were comparable between patients continuing bimekizumab or switching from secukinumab to bimekizumab. The incidence of serious adverse events was low. These analyses included 336 patients treated with bimekizumab, and 318 patients treated with secukinumab who completed the BE RADIANT double-blinded period and entered the OLE. 
 

BE RADIANT open-label extension study in patients with moderate to severe plaque psoriasis: responder analysis in patients switching from secukinumab to bimekizumab3 

At week 48, 53/318 patients (16.7 percent) treated with secukinumab had not achieved PASI90. After switching to bimekizumab in the OLE, responses improved. At week 96, 79.2 percent of this group achieved PASI90 and 50.9 percent achieved PASI100. At week 48, 256/318 patients (80.5 percent) treated with secukinumab had achieved PASI90. After switching to bimekizumab in the OLE, 95.2 percent of this group maintained this response at week 96 and the PASI100 response increased from 65.2 percent at week 48 to 79.9 percent at week 96. No clinically relevant differences in safety outcomes for patients who switched from secukinumab to bimekizumab were observed from weeks 48-96.

*In the EU the recommended bimekizumab dose for adult patients with plaque psoriasis is 320 mg (given as two subcutaneous injections of 160 mg) at week 0, four, eight, 12, 16 and every eight weeks thereafter. For some patients with a body weight ≥120 kg who did not achieve complete skin clearance at week 16, 320 mg every four weeks after week 16 may further improve treatment response.4 

¥ Modified non-responder imputation analyses

References

  1.  Gordon KB, Armstrong A, Lebwohl M et al. Bimekizumab efficacy and safety through two years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. To be presented at the 2022 AAD Annual Meeting.
  2. Strober B, Paul C, Blauvelt A et al. Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial. To be presented at the 2022 AAD Annual Meeting. 
  3. Lebwohl M, Ghoreschi K, Strober B et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial To be presented at the 2022 AAD Annual Meeting. 
  4. BIMZELX (bimekizumab) EU Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf Last accessed March 2022.
  5. BIMZELX (bimekizumab) GB Summary of Product Characteristics https://www.medicines.org.uk/emc/product/12834
    https://www.medicines.org.uk/emc/product/12833

Commenta questo articolo:

*
Il tuo indirizzo email non sarà visibile agli altri utenti.
Il commento sarà pubblicato solo previa approvazione del webmaster.